EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease

Sweta Ghosh, Rajbir Singh, Zachary Matthew Vanwinkle, Craig James McClain, Vatsalya Vatsalya, Bodduluri Haribabu, Praveen Kumar Vemula, Venkatakrishna Rao Jala

Frontiers in Pharmacology · 19.01.2026 · 16

DOI: 10.3389/fphar.2025.1706111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.01.2026. Verfasst von Sweta Ghosh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Lo…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NIGMS NIH HHS, NIAAA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Excessive alcohol consumption poses a significant global health concern, ranking as the world’s third-largest risk factor for diseases and disabilities, contributing to 5.9% of all deaths worldwide. Among various disorders linked to alcohol misuse, alcohol-associated liver disease (ALD) is the most prominent. ALD patients often exhibit increased intestinal permeability, systemic inflammation, gut dysbiosis, and hepatic steatosis. No FDA-approved therapies are available to treat ALD or to resolve the pathological domains of alcohol-induced gut barrier dysfunction, inflammation, and steatosis. The goal of this study is to investigate the potential therapeutic role of the microbial metabolite Urolithin A’ (UroA), in alleviating ALD.

Methods

Caco-2 (monolayer colon epithelial) cells and AML12 (hepatocytes) cells were used to test the protective activities of UroA against EtOH-induced gut barrier dysfunction and lipid accumulation in vitro. Preclinical ALD mouse models were used to test the therapeutic potential of UroA against EtOH exposure. Additionally, we generated cell-specific deletion mice with aryl hydrocarbon receptor (AHR) deletion to define the role of intestinal epithelial cell AHR in UroA-mediated protective activities against ALD.

Results

The results presented here demonstrate the efficacy of UroA as a potential therapeutic agent to protect against EtOH-induced disruption of tight junction proteins, inflammation, and lipogenesis both in vitro and in vivo models.

Conclusion

Our findings suggest that the simultaneous targeting of gut barrier dysfunction, inflammation, and hepatic steatosis by treatment with UroA may offer new possibilities for combating ALD. Moreover, our results suggest that UroA-mediated protective activities against EtOH-induced gut barrier dysfunction and inflammation in ALD are dependent on intestinal epithelial cell-AHR.

Schlagwörter

Stichwörter der Autor:innen

alcohol-associated liver diseasearyl hydrocarbon receptorgut barrier functioninflammationsteatosisurolithin A

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, United States.
  • Department of Medicine, University of Louisville, Louisville, KY, United States.
  • Department of Pharmacology & Toxicology, University of Louisville, Louisville, KY, United States.
  • Hepatobiology & Toxicology Center, University of Louisville, Louisville, KY, United States.
  • Alcohol Research Center, University of Louisville, Louisville, KY, United States.
  • Robley Rex Louisville VAMC, Louisville, KY, United States.

Förderung

  • NIEHS NIH HHS
  • NIGMS NIH HHS
  • NIAAA NIH HHS
  • NCRR NIH HHS
  • NIDDK NIH HHS
  • CSRD VA
  • NCI NIH HHS

Zitieren

APA

Ghosh, S., Singh, R., Vanwinkle, Z. M., McClain, C. J., Vatsalya, V., Haribabu, B., Vemula, P. K., & Jala, V. R. (2026). Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1706111

Vancouver

Ghosh S, Singh R, Vanwinkle ZM, McClain CJ, Vatsalya V, Haribabu B, et al. Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1706111

BibTeX
@article{Ghosh2026,
  author = {Ghosh, Sweta and Singh, Rajbir and Vanwinkle, Zachary Matthew and McClain, Craig James and Vatsalya, Vatsalya and Haribabu, Bodduluri and Vemula, Praveen Kumar and Jala, Venkatakrishna Rao},
  title = {Urolithin A regulates gut: liver axis to ameliorate alcohol-associated liver disease},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fphar.2025.1706111}
}
Kostenlos starten →